Highest-materiality recent filing
ZyVersa Therapeutics downgraded from OTCQB to OTC Pink Limited Market
Effective July 16, 2026, ZyVersa ceased trading on OTCQB and began trading on OTC Pink Limited Market.
Director Min Chul Park resigned effective July 8, 2026, for personal reasons, no disagreement with company.
ZyVersa raises $1M via convertible notes and warrants for working capital
Issued $1M aggregate principal 10% convertible promissory notes, maturing in 12 months, with a $0.02 floor price on conversion.
ZyVersa director Robert Finizio resigns from board effective Dec 2, 2025
Independent director Robert G. Finizio resigned as board member, Compensation Committee chair, and Audit Committee member.
ZyVersa reports Q3 net loss of $19.8M; cash only $0.5M, going concern risk
Cash on hand $0.5M as of Sept 30, 2025; expects month-to-month liquidity only, needs additional financing.
ZyVersa CMO Pablo Guzman resigns Oct 10, 2025 to focus on family
Pablo Guzman, M.D., resigned as CMO and SVP of Medical Affairs, effective October 10, 2025.
Nasdaq to delist ZyVersa Therapeutics common stock effective ~Sep 28, 2025
Nasdaq notified ZyVersa on Sept 14, 2025, of delisting; Form 25 to be filed on or about Sept 18, 2025.
ZyVersa Therapeutics common stock to trade on OTCQB from July 28
OTCQB approval received on July 25, 2025; trading commences July 28 under ticker ZVSA.
ZyVersa Therapeutics receives Nasdaq delisting notice; trading suspended July 17
Nasdaq Hearings Panel denied request to continue listing on the Nasdaq Capital Market.
ZyVersa enters warrant exercise inducement; expected gross proceeds ~$2.05M
Existing Series A-2 and A-3 warrants with $1 exercise price reduced to $0.67; holder exercises for cash.
Up to $10M of common stock; company controls timing and amount of sales over 24-month term.
ZyVersa shareholders approve up to 3.84M new shares, potentially doubling float
Shareholders approved increasing equity plan share reserve by 100,000 to 382,122 shares.
Zyversa receives Nasdaq delisting notice for low bid price; will appeal
Received Nasdaq letter on May 27, 2025 for non-compliance with $1.00 minimum bid price rule.
Marcum resigned as auditor effective April 4, 2025; CBIZ CPAs engaged April 7 after acquiring Marcum's attest practice.
ZyVersa raises ~$2M in private placement; special meeting adjourned without quorum
Gross proceeds of $2M from private placement of pre-funded and common warrants; pre-funded warrants priced at $0.9499.
ZyVersa Q3 net loss $2.4M, cash only $0.1M; Phase 2a trial expected Q1 2025
Net loss improved 17.3% to $2.4M from $2.9M YoY; R&D and G&A expenses decreased.
ZyVersa raises ~$1.7M via warrant exercise inducement at $2.06/share
Existing warrant holders exercise at reduced price of $2.06/share; gross proceeds ~$1.7M.
ZyVersa shareholders approve 150,000-share equity plan increase and up to 478,600 warrant shares
Elected Min Chul Park, Ph.D. as Class II director with 183,493 votes for, 13,425 withheld.
Zyversa Therapeutics enters $1.4M ATM equity offering with A.G.P.
Entered ATM Agreement with A.G.P./Alliance Global Partners to sell up to $1,397,396 of common stock.
ZyVersa raises ~$830k via warrant inducement at $3.46; issues 200% new warrants
Holder exercises existing Series A/B warrants at reduced price $3.46 (from $12.50), gross proceeds ~$830k.
ZyVersa Therapeutics executes 1-for-10 reverse stock split effective April 25, 2024
Reverse split ratio 1-for-10; approved by stockholders at special meeting on April 17, 2024.
ZyVersa shareholders approve reverse stock split; board sets 1-for-10 ratio
Shareholders approved reverse stock split at special meeting on April 17, 2024, with 2,058,182 votes for and 899,831 against.
Nasdaq staff determined July 2023 offering required stockholder approval; issued Letter of Reprimand, no further action.
Received Nasdaq approval on Feb 29, 2024 to transfer listing from Global Market to Capital Market.
ZyVersa Therapeutics dismisses Ernst & Young, appoints Marcum as auditor
Dismissed EY as independent auditor on Dec 22, 2023; EY served from 2019 through Q3 2023 and interim period.
ZyVersa Therapeutics prices $5.0M public offering of common stock and warrants
Offering of 4M shares (or pre-funded warrants in lieu) plus 4M Series A and 4M Series B warrants at combined $1.25 per unit.
ZyVersa Therapeutics approves 1-for-35 reverse stock split and increases authorized shares to 251M
Reverse split 1:35 effective Dec 4, 2023 at 4:01 pm ET; adjusted trading begins Dec 5 under ZVSA.
ZyVersa receives Nasdaq delisting determination over low bid price; hearing requested
Nasdaq determined to delist on Nov 16, but company requested hearing, staying delisting pending panel decision.
Elected Class I directors Gregory G. Freitag and James Sapirstein with ~12.1M votes each.
ZyVersa Therapeutics raises ~$966k via warrant exercise at reduced price of $0.1357 per share
Holder exercised 7,121,213 shares of common stock at reduced exercise price of $0.1357 per share.
ZyVersa Therapeutics induces warrant exercise for up to 12.1M shares; issues new warrants
Holder to exercise up to 12,121,213 existing warrants at reduced price (lower of that day's close or 5-day average) by Sep 18, 2023.
ZyVersa receives Nasdaq notice for non-compliance with minimum MVPHS of $5M
Nasdaq letter dated Sept 1, 2023 for failure to meet minimum Market Value of Publicly Held Shares of $5M.
ZyVersa CSO retiring Aug 18; annual meeting Oct 31, proposal deadline Aug 30
CSO Nicholas A. LaBella, Jr. notified planned retirement effective August 18, 2023.
ZyVersa prices $2.1M public offering and extends investor lockup
Priced 'reasonable best efforts' public offering of ~12.7M shares/pre-funded warrants plus common warrants at $0.165/unit for ~$2.1M gross proceeds.
ZyVersa receives Nasdaq delisting notice for $1.00 bid price non-compliance
Received Nasdaq notice on June 9, 2023 for failing to maintain $1.00 minimum bid price over 30 consecutive business days.
ZyVersa Therapeutics board members Katrin Rupalla and Daniel O'Connor resign effective May 18
Dr. Katrin Rupalla resigned to pursue opportunity that precludes board service.
ZyVersa Q1 2023 net loss $3.5M; cash only $1.3M, needs financing
Cash of $1.3M as of March 31, 2023, sufficient only on month-to-month basis; company requires additional financing.
ZyVersa reports $14.1M net loss for 2022, cash $5.9M; plans VAR 200 trial in Q4 2023
No revenue in 2022; net loss of $14.1M combined (up 75% from $8.1M in 2021).
ZyVersa files Section 205 petition to validate charter amendment after Boxed decision uncertainty
Filed petition in Delaware Chancery on March 9, 2023 seeking validation of Second Amended and Restated Certificate of Incorporation and all shares issued.
LFR waives termination rights for $1M milestone payments until March 31, 2023, contingent on ZyVersa forgiving $351,579 note and paying $648,421 cash.
ZyVersa amends pro forma to reflect reverse merger; adds ~$105M IPR&D asset
Pro forma updated to forward merger (ZyVersa as VIE); ~$105M IPR&D/goodwill recorded on balance sheet.
ZyVersa grants 100,000-share option inducement to new CMO Dr. Pablo Guzman at $2.11
Nonqualified stock option to purchase 100,000 shares at $2.11/share, the Jan 25, 2023 closing price.
ZyVersa appoints Sapirstein, Freitag, and Rupalla to board post-business combination
ZyVersa appoints James Sapirstein (FWBI CEO), Gregory Freitag (PDSB board), and Katrin Rupalla to its board effective Jan 5, 2023.
ZyVersa extends waiver of $1.5M milestone payments due to L&F Research to March 31, 2023
Second Amendment to Waiver extends L&F Research's forbearance on terminating license for non-payment of $500K IND Milestone and two $500K Phase 1/2 milestone payments.
ZyVersa reports Q3 2022 net loss of $3.7M, R&D spend up 473% YoY
Net loss of $3.693M for Q3 2022 vs $1.879M in Q3 2021; nine-month loss $9.445M.
ZyVersa Therapeutics completes de-SPAC merger with Larkspur; 99% of public shares redeemed
Larkspur merged with ZyVersa on Dec 12, 2022; name changed to ZyVersa Therapeutics, Inc. (ZVSA).
Larkspur Health Acquisition Corp. stockholders approve ZyVersa merger; 7.7M shares redeemed
Stockholders approved business combination with ZyVersa Therapeutics: 6,543,525 for, 785,791 against.
SPAC Larkspur (LSPR) entered into Business Combination Agreement with ZyVersa Therapeutics, a clinical-stage biopharma targeting renal and inflammatory diseases.
Raj Mehra removed as Audit Committee Chair after Board found he was not independent under SEC/Nasdaq rules.
Larkspur Health Acquisition units may separate into common stock and warrants starting Feb 10, 2022
Units trade as LSPRU; separated common stock as LSPR, warrants as LSPRW on Nasdaq.
On August 7, 2023, Nicholas A. LaBella, Jr., Chief Scientific Officer and Senior Vice President of Research and Development at ZyVersa Therapeutics, Inc. (the “Company”) notified the Company of his planned retirement from the Company effective August 18, 2023.
On May 17, 2023, Katrin Rupalla, Ph.D., notified the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc. (the “Company”) that she was resigning from the Board effective May 18, 2023.
On May 17, 2023, Daniel J. O’Connor, notified the Board of the Company that he was resigning from the Board effective May 18, 2023.
On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).
On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).
On January 5, 2023, the Board of Directors (the “Board”) of ZyVersa Therapeutics, Inc., a Delaware corporation (the “Company” or “ZyVersa”), appointed James Sapirstein, Gregory Freitag, and Katrin Rupalla to serve as members of the board to fill the three vacancies created as a result of the business combination between ZyVersa Therapeutics, Inc., a Florida corporation (“Old ZyVersa”) with Larkspur Health Acquisition Corp. (“Larkspur”), which was consummated on December 12, 2022 (the “Business Combination”).
Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company
Nicholas A. LaBella was appointed Chief Scientific Officer
Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company
Stephen C. Glover, Robert Finizio, Min-Chul Park, and Daniel J. O’Connor were appointed as directors of the Company
David S. Briones, Raj Mehra, Gregory Skalicky, and Christopher Twitty ceased serving on the Board
Stephen C. Glover was appointed President and Chief Executive Officer
Max materiality 1.00 · Median 0.60 · Most common event other_material